Whole exome sequencing of primary tumors in papillary thyroid microcarcinoma with and without lymph node metastasis
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Papillary thyroid microcarcinoma (PTMC) generally has an excellent prognosis, and active surveillance is increasingly considered for carefully selected patients with low-risk disease. However, evidence of tumor progression or suspected lymph node metastasis (LNM) may warrant surgical intervention. Understanding the genomic characteristics of PTMC according to LNM status may provide additional insights into the biological heterogeneity of these tumors. Methods Whole-exome sequencing (WES) was performed on primary tumor specimens from 72 patients with PTMC, including 42 patients with pathologically confirmed LNM (LNM-positive group) and 30 without LNM (LNM-negative group). Detected genomic variants and estimated mutational signatures were compared between groups. Exploratory subgroup analyses were performed according to sex and LNM status, and the potential functional effects of missense variants were assessed using SIFT and PolyPhen-2. Results 42 LNM-positive patients were younger and more frequently male than 30 LNM-negative patients. The number of filtered variants differed between groups ( p = 0.027). BRAF missense variants were detected in 46 of 72 patients (63.9%), including V600E in 45 patients and K601E in one patient. Exploratory subgroup analyses identified candidate genomic alterations, including variants in Hippo pathway-associated genes, among male LNM-positive patients. Conclusions This study identified differences in filtered genomic variant profiles between LNM-negative and LNM-positive PTMC groups, alongside frequent BRAF alterations and exploratory candidate variants in Hippo pathway-associated genes. Although further validation is required, these findings provide additional insights into the genomic heterogeneity of PTMC and highlight candidate alterations and pathways for future investigations.
Source: Frontiers in Oncology
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Award: G9001397391
OpenAlex ID: W7235842845
